Workflow
2 Soaring Stocks That Could Climb 68% to 166% Higher in 2025, According to Wall Street
SMMTSummit Therapeutics (SMMT) The Motley Fool·2024-12-15 12:37

Core Insights - The stock market has performed well in 2024, with significant gains for Viking Therapeutics and Summit Therapeutics, whose shares have more than doubled [1] Group 1: Viking Therapeutics - Viking Therapeutics' stock increased by 157% from the end of 2023 to December 12, 2024, driven by the potential success of its experimental weight loss treatment VK2735 [3] - VK2735 is a dual GLP-1 and GIP receptor agonist, similar to Eli Lilly's tirzepatide, which has seen substantial sales growth, reaching 11billioninthefirstninemonthsof2024[4]−Mid−stageclinicaltrialresultsindicatethatVK2735couldcaptureasignificantmarketshare,withpatientsinarecentstudylosing8.211 billion in the first nine months of 2024 [4] - Mid-stage clinical trial results indicate that VK2735 could capture a significant market share, with patients in a recent study losing 8.2% of their weight after four weeks [5] - An earlier trial of an oral version of VK2735 showed a 5.3% weight reduction in patients after 28 days [6] Group 2: Summit Therapeutics - Summit Therapeutics has licensed ivonescimab, a bispecific antibody that targets both PD-1 and VEGF, which has shown promising results in lung cancer patients compared to Keytruda [7][8] - The stock of Summit Therapeutics surged by approximately 583% in 2024, reflecting investor optimism about ivonescimab's potential [7] - The company is currently conducting a phase 3 trial for ivonescimab in the U.S., with expectations of success based on prior results from China [10] - Summit Therapeutics' market cap recently reached 13.2 billion, but there are concerns about the sustainability of this valuation if long-term survival data does not meet expectations [13]